Clinical Research Hospitals Pharmacy White Paper 
FDA Law Blog: Biosimilars
APRIL 8, 2024
Department of Health and Human Services (HHS) recently published a White Paper on Policy Considerations to Prevent Drug Shortages and Mitigate Supply Chain Vulnerabilities in the United States —with input from several HHS stakeholders, including FDA, CMS, and the Administration for Strategic Preparedness and Response. By Kalie E.
Agency IQ
APRIL 12, 2024
In addition, trial sites tend to be concentrated in highly specialized clinical sites and hospital networks, so rural populations and those who receive their health care from community health centers or networks will also have limited opportunities to participate in clinical trials under more traditional models.
Expert insights. Personalized for you.
59 
Let's personalize your content